Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 10/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 10/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | TOP2A | P11388 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.45 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18152295 | 1.00 | BCL9 (0.47) | BCL9CTNNB1GPR119TOP2APIK3CD | |
| SCHEMBL30350445 | 1.00 | BCL9 (0.47) | BCL9CTNNB1GPR119TOP2APIK3CD | |
| SCHEMBL18152414 | 1.00 | BCL9 (0.47) | BCL9CTNNB1GPR119TOP2APIK3CD | |
| SCHEMBL18152370 | 0.92 | BCL9 (0.48) | BCL9CTNNB1USP30 | |
| SCHEMBL30392132 | 0.91 | PIK3CD (0.47) | BCL9CTNNB1GPR119PIK3CDPIK3CA | |
| SCHEMBL30350485 | 0.91 | PIK3CD (0.47) | BCL9CTNNB1GPR119PIK3CDPIK3CA | |
| SCHEMBL18152375 | 0.91 | TOP2A (0.47) | BCL9CTNNB1GPR119TOP2APIK3CD | |
| SCHEMBL18152288 | 0.91 | TOP2A (0.47) | BCL9CTNNB1GPR119TOP2APIK3CD | |
| SCHEMBL18152287 | 0.91 | TOP2A (0.47) | BCL9CTNNB1GPR119TOP2APIK3CD | |
| SCHEMBL30643913 | 0.88 | GPR119 (0.47) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542250-B2 | Inhibitors for the B-catenin/B-cell lymphoma 9 (BCL9) protein-protein interaction | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210179583-A1 | INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 (BCL9) PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-06-17 | — | — | US | disclosed |
| US-20210078986-A1 | INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 (BCL9) PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-03-18 | — | — | US | disclosed |
| WO-2016168524-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542250-B2 | Inhibitors for the B-catenin/B-cell lymphoma 9 (BCL9) protein-protein interaction | BCL9, BCL9L, BCL3 | BCL9 1/4885CTNNB1 7/4885GPR119 2136/4885 |
| US-20210078986-A1 | INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 (BCL9) PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL3 | BCL9 1/4885CTNNB1 7/4885GPR119 2323/4885 |
| US-20210179583-A1 | INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 (BCL9) PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL3 | BCL9 1/4885CTNNB1 7/4885GPR119 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.